MedTrace Logo

A Digimed Oncology PharmacoTherapy Registry

NCT04088955 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-03-11

No results posted yet for this study

Summary

DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity.

The aim of this registry is to collect and analyze data on the use of DigiMeds™ and a digital feedback system on medication adherence, patient-provider communication, and data-driven optimization of therapy for cancer patients.

Conditions

Interventions

OTHER

DigiMeds

Digitized Capecitabine

Sponsors & Collaborators

  • Proteus Digital Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Sinette Heys · Proteus Digital Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-06
Primary Completion
2021-09-30
Completion
2022-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088955 on ClinicalTrials.gov